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Purpose: Corneal fibrosis is 3rd leading cause of global blindness according to WHO report. At 
present, no agents are proven to clinically reduce corneal fibrosis without causing significant 
side effects. It was hypothesized that decorin gene delivered into keratocytes prevents corneal 
fibrosis in the cornea in vivo by blocking transforming growth factor β (TGFb), which converts 
keratocyte to myofibroblasts and cause fibrosis. 
Methods: New zealand White rabbits were used. Fibrosis in the cornea was produced with 
photorefractive keratectomy (PRK) using excimer laser. 50µl AAV5 titer (5X1012 vg/ml) 
expressing decorin was topically applied on the PRK-treated and untreated eyes. Slitlamp 
biomicroscopy was used to evaluate the health of the eye and clinical scoring of corneal haze. 
Real-time PCR, immunoblotting and immunocytochemistry techniques were used to measure the 
hallmarks of fibrosis [alpha smooth muscle actin (aSMA), F-actin and fibronectin]. Transmission 
electron microscopy investigated ultrastructural features. Dot-blot and real-time PCR quantified 
delivered-decorin gene copies.
Results: The AAV-decorin treated rabbit eyes did not show inflammation, redness or structural 
changes in the cornea in slitlamp biomicroscopy. A statistically significant (44.9-67.4%±4.3; 
p <0.001) decrease in the expression of fibrotic markers (aSMA, F-actin and fibronectin) 
was detected with immunocyctichemistry and immunoblotting in decorin-delivered corneas. 
Significantly high (8-10 fold, p<0.001) decorin mRNA expression was noted in AAV-DCN-
treated rabbit corneas. 
Conclusions: AAV-mediated decorin gene therapy can effectively reduce fibrosis in the rabbit 
cornea in vivo. Our preclinical studies suggest that decorin gene therapy has potential for treating 
corneal haze in patients, and set the stage for undertaking clinical trials.
